For instance, ALK point mutations were permitted in some studies, and mutations such as F1174L (common ALK‐activating mutations seen in neuroblastoma) have been shown to confer resistance to crizotinib in neuroblastoma and other cancers82. The gene discussed is ALK; the disease is neuroblastoma.